Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

May 31, 2026

Conditions
ROSAH
Interventions
DRUG

DF-003

140 mg on Days 1, 2, and 3 followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.

Trial Locations (4)

2000

RECRUITING

Save Sight Institute - University of Sydney Eye Hospital, Sydney

20892

WITHDRAWN

National Institutes of Health Clinical Center, Bethesda

27705

RECRUITING

Duke Eye Center - Duke University Hospital, Durham

84132

RECRUITING

John A. Moran Eye Center - University of Utah Health, Salt Lake City

All Listed Sponsors
lead

Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)

INDUSTRY